The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs could
Parkinson's disease, a devastating neurodegenerative disorder, is characterized by the relentless loss of dopaminergic neurons, which leads to significant motor dysfunction and a decline in overall quality of life. Central to the pathology of PD are aggregates of alpha-synuclein protein and
The University of Manchester recently celebrated a significant milestone with the launch of the British Heart Foundation (BHF) Manchester Center of Research Excellence. Supported by a substantial £4 million grant from the BHF, this new center is set to advance world-class cardiovascular research
The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can
Antibody-drug conjugates (ADCs) are emerging as a groundbreaking approach in oncology, offering the potential to revolutionize cancer treatment through targeted and effective therapies. This innovation combines the precision of targeted antibodies with the potent cell-killing ability of
The recent announcement by Bayer AG and BlueRock Therapeutics LP marks a significant milestone in the development of cell therapies aimed at vision restoration. The FDA has granted Fast Track designation to OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases such as
